Lung cancer and pulmonary metastases remain the leading cause of cancer-related mortality.
While surgery is the gold standard, local tissue-ablative therapies are increasingly used in unresectable disease or inoperable patients.
Minimally invasive local control presents a safe, repeatable approach to slow disease progression and prolong survival.
